Clinical Trial

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

Study acronym: COSENSE-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 and older, with microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC), that is incurable or not resectable with curative intent.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-26; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06907342
Lead Sponsor St. Olavs Hospital
Collaborators: Norwegian University of Science and Technology
Conditions Tumor, Colorectal, Organoids, Tumoroid, Metastatic Colorectal Cancer, Core Needle Biopsy, First-line Treatment
Enrollment 148 participants
Start Date 2025-05-23
Primary Completion 2027-12 (estimated)
Study Completion 2040-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-20